Exo-spin™ technology combines precipitation and size exclusion chromatography (SEC), making it superior to other techniques that rely solely on one method. Using only precipitation for exosome isolation will result in co-purification of large amounts of non-exosomal proteins and other material as well as carryover of the precipitant. SEC is reliable for exosome isolation, but a precipitation step is needed to concentrate your sample prior to SEC isolation. If there is no precipitation, a lower exosome recovery will be observed. We provide a simple two-step protocol which allows you to purify your sample in less than 2 hours with consistent and reliable results!

The EX01 Exo-spin™ kit has been developed to process up to 50 ml of cell culture medium, saliva, urine, cerebrospinal fluid (CSF), human breast milk and other low-protein biological fluids. The kit includes Exo-spin™ buffer as well as SEC columns. The Exo-spin™ buffer is a polymer-based precipitation buffer and will be used for the first step. For the second step, pre-packed and equilibrated ready-to-use SEC columns are included.

Which Exo-spin™ kit shall I choose for my sample volume?* For cerebrospinal fluid (CSF) and human breast milk samples, validated protocols are available for EX01 only. The protocols are provided in the user guides. 

Exo-spin™ column and resin pore size

The column bed volume is 500 µl, allowing for 100 µl of volume to be loaded on top of the column.

The pore size of the resin is approximatively 30 nm to attain a highly pure exosome elution. All other molecules (e.g. proteins, lipids) which are smaller than 30 nm will enter into the pores and remain trapped in the column.

Highest recovery and purity

As mentioned above, essentially all proteins and lipids will be retained in the column and will elute later than the exosomes, ensuring a highly pure sample ready for your downstream application.

Reproducibility

All our columns are manufactured in our laboratory to ensure a high reproducibility between each lot. As proof of reproducibility and batch-to-batch consistency, a large number of peer-reviewed scientific papers have been published describing the use of Exo-spin™.

Storage

Upon receipt, store purification columns and Exo-spin™ Buffer at 4°C. All other components should be stored at room temperature (15°C – 25°C).

Frequently Asked Questions (FAQs)

For any additional questions, please refer to FAQs document below.

Start today! Select our starter pack

We designed the ideal starter pack to guide your exosome research. The starter pack includes the exosome purification kit of your choice, exosome validated antibodies, and NTA profiling analysis. The complete details can be found in the product page here.

[accordions]
[accordion title=”key features”]

NTA measurement of samples prepared from cell culture medium: (a) Exo-spin™ yields significantly higher numbers of vesicles of the expected 40-120 nm size range than alternatives including (b) ultracentrifugation (c) competitor kit. The size distribution profile obtained with Exo-spin™ most closely resembles ultra-centrifugation. Lower rRNA contamination levels Analysis on Bioanalyzer instrument shows RNA preps (Trizol) following (d) Exo-spin™ purification from cell culture samples compared with (e) ultracentrifugation or (f) competitor kit.

EX01 Exo-spin™ kit comparative data

Data determined by nanoparticle tracking analysis (NTA). Each curve represents the average of 3 technical replicate measurements for each exosome isolation method triplicate experiment. (PM = Precipitation Method). Figure taken and adapted from (Martins, TS et al., 2018).

Characterizing Exo-spin™ isolated exosomes using nanoparticle tracking analysis (NTA)

Exosome characterization with NTA. Exosomes have been isolated using the Exo-spin™ kit and analysis performed with the ZetaView® instrument.

[/accordion]

[accordions]
[accordion title=”Downstream applications”]

The EX01 Exo-spin™ kit is compatible with all downstream application and has been published in a large range of different applications.

RNA analysis:

• Li Z, Mbah NE and Maltese WA. (2018). Vacuole-inducing compounds that disrupt endolysosomal trafficking stimulate production of exosomes by glioblastoma cells. Molecular and Cellular Biochemistry 439(1-2):1-9.
• Koo KM, Wee EJ and Trau M.; (2016). Colorimetric TMPRSS2-ERG Gene Fusion Detection in Prostate Cancer Urinary Samples via Recombinase Polymerase Amplification. Theranostics 6(9): 1415–1424.
• Yoon C, Kim J, Park G, Kim S, Kim D, Hur DY, Kim B and Kim YS. (2016). Delivery of miR-155 to retinal pigment epithelial cells mediated by Burkitt’s lymphoma exosomes. Tumor Biology 37(1):313-21.

Exosome engineering for therapeutic cargo:

• Kojima R, Bojar D, Rizzi G, Hamri GC, El-Baba MD, Saxena P, Ausländer S, Tan KR and Fussenegger M. (2018). Designer exosomes produced by implanted cells intracerebrally deliver therapeutic cargo for Parkinson’s disease treatment. Nature communications 9: 1305.

Functional study:

Pop-Up Link

• Piao YJ, Kim HS, Hwang EH, Woo J, Zhang M and Moon WK. (2017). Breast cancer cell-derived exosomes and macrophage polarization are associated with lymph node metastasis. Oncotarget 9(7): 7398–7410.

Proteomic (MS/MS analysis):

• E L Kavanagh, S Lindsay, M Halasz, L C Gubbins, K Weiner-Gorzel, M H Z Guang, A McGoldrick, E Collins, M Henry, A Blanco-Fernández, P O’ Gorman, P Fitzpatrick, M J Higgins, P Dowling, and A McCann. (2017). Protein and chemotherapy profiling of extracellular vesicles harvested from therapeutic induced senescent triple negative breast cancer cells. Oncogenesis 6(10): e388.

Application note:

• Exosome isolation from cerebrospinal fluid (CSF).pdf

[/accordion]

[accordion title=”User guide”] EX01 Exo-Spin user gEX01_Exo-spin_User_Guideuide[/accordion]

[accordion title=”FAQs”] FAQs[/accordion]
[accordion title=”MSDS/Tech Sheet”] EX01 and EX02 MSDS.pdf[/accordion]
[accordion title=”Product Brochure”] CellGS exosome brochure.pdf[/accordion]
[/accordions]